Gingival Fibroblast Conditioned Medium Inhibits Cancer Invasion

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current cancer treatments targeting tumor invasion and metastasis, particularly using cell-derived products, have shown inconsistent results and lack clinical assessment, with limited understanding of how different cell types influence tumor progression.

Innovation Solution

The use of gingival fibroblast-derived products, specifically conditioned medium, is found to inhibit malignant cell invasion, offering a potential therapeutic approach for preventing or treating cancer by administering a prophylactically or therapeutically effective quantity of these products.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cell-derived products are used to inhibit tumor invasion, then cancer progression may be inhibited, but treatment efficacy is inconsistent and lacks clinical assessment

Engineering Contradiction:
Improvetreatment efficacyVSAvoidclinical applicability
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent uses conditioned medium from gingival fibroblasts as an intermediary substance to mediate the inhibition of tumor cell invasion. This conditioned medium contains secreted factors that specifically target and inhibit invasive processes without requiring direct cell-cell contact or complex immunological mechanisms, thereby providing reliable and consistent treatment effects that can be standardized for clinical use.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Adaptability or versatility

If different cell types are used to influence tumor progression, then various biological effects can be achieved, but results are inconsistent and sometimes opposite

Engineering Contradiction:
Improvebiological effect diversityVSAvoidtreatment consistency
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent specifically selects gingival fibroblasts as the cell source, exploiting their unique local characteristics - their natural function in extracellular matrix remodeling and their specific secretory profile. This localized specialization of gingival fibroblasts (rather than using generic fibroblasts or other cell types) provides consistent anti-invasive effects while maintaining the biological versatility needed to target multiple aspects of tumor progression.

Inventive Principle:
Principle #3Local quality

Data Source

PatentEP2403508B1Method of treating cancer employing gingival fibroblast conditioned medium
Publication Date: 2015.10.28 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (APHP)
  • EP2403508B1 patent drawingFigure 1
  • EP2403508B1 patent drawingFigure 2
  • EP2403508B1 patent drawingFigure 3

AI summary

The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.